Stockscreener 앱 받기
11.74
9.55%
-1.24
시간 외 거래:
11.45
-0.29
-2.47%
전일 마감가:
$12.98
열려 있는:
$12.55
하루 거래량:
105.52K
Relative Volume:
1.11
시가총액:
$7.19M
수익:
$10.48M
순이익/손실:
$-37.74M
주가수익비율:
-0.7254
EPS:
-16.1846
순현금흐름:
$-29.03M
1주 성능:
+10.03%
1개월 성능:
+168.65%
6개월 성능:
-54.85%
1년 성능:
-97.54%
1일 변동 폭
$11.15
$12.84
1주일 범위
$10.41
$13.25
52주 변동 폭
$4.02
$532.50
재규어 헬스 Stock (JAGX) Company Profile
명칭
Jaguar Health Inc
전화
415-371-8300
주소
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
JAGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
11.74 | 7.19M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.50 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
재규어 헬스 Stock (JAGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-07-11 | 개시 | Rodman & Renshaw | Buy |
재규어 헬스 주식(JAGX)의 최신 뉴스
SEC Form 424B5 filed by Jaguar Health Inc. - Quantisnow
Geode Capital Management LLC Has $98,000 Position in Jaguar Health, Inc. (NASDAQ:JAGX) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Jaguar Health (JAGX) Reports Positive Trial Results for Crofelemer Formulation | JAGX Stock News - GuruFocus
Jaguar Health to Present at BioTrinity 2023 Conference’s R&D Spotlight on Rare Diseases - ACCESS Newswire
Jaguar Health Announces Promising Crofelemer Trial Results - TipRanks
Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5%Potential to Modify Disea - Yahoo Finance
REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Pre - GuruFocus
Breakthrough Data: New Treatment Hope for Ultra-Rare Pediatric Disease MVIDKey Results Revealed - Stock Titan
Jaguar Health to Present Initial Results from the Proof-of-Conce - GuruFocus
Jaguar Health (JAGX) to Host Webcast on Crofelemer Trials for Ra - GuruFocus
Jaguar Health Schedules Webcast on Crofelemer Trial Results - TipRanks
Breakthrough Clinical Data: New Treatment Hope for Two Ultra-Rare Intestinal Diseases Shows Early Promise - Stock Titan
Form 8-K/ACurrent report: [Amend] - ADVFN
Jaguar Health's (JAGX) Crofelemer Shows Promise in Breast Cancer Subgroup - GuruFocus
Jaguar Health Presents at Elite Ped-GI Congress 2025 - TipRanks
Jaguar Health (JAGX) Reports Progress in Rare Disease Drug Trial - GuruFocus
Jaguar Health's (JAGX) Crofelemer Trial Shows Promise for Rare Disorders | JAGX Stock News - GuruFocus
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress | JAGX Stock News - GuruFocus
First-Ever MVID Treatment? Crucial Trial Data for Orphan Drug Crofelemer Coming to Elite Congress - Stock Titan
Jaguar Health to present results from OnTarget study in breast cancer patients - Yahoo Finance
Jaguar Health to discuss breast cancer treatment with FDA By Investing.com - Investing.com South Africa
Jaguar Health (JAGX) Advances OnTarget Study with Key Presentati - GuruFocus
Jaguar Health to discuss breast cancer treatment with FDA - Investing.com
Jaguar Health Announces Significant Results in Breast Cancer Pat - GuruFocus
Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting | JAGX Stock News - GuruFocus
Game-Changing Results: New Cancer Drug Shows Remarkable Success in Breast Cancer Patients - Stock Titan
Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2024 Earnings Call Transcript - MSN
Jaguar Health's Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea - ACCESS Newswire
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting - GuruFocus
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product - markets.businessinsider.com
Revolutionary Pain Relief: New FDA-Approved Treatment Transforms Cancer Care Experience - Stock Titan
Jaguar Health's Italian Subsidiary Napo EU Appoints Annabella Amatulli Chief Regulatory Officer - ACCESS Newswire
Jaguar Health (NASDAQ:JAGX) Shares Cross Below Two Hundred Day Moving Average – What’s Next? - Defense World
재규어 헬스 (JAGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):